Immuron Hires Pullan To Find Partner For Gut Infection Drug, Seeks Strategic Partner For FDA-Cleared IMM-529 Trial
Immuron Limited ((ASX: IMC, NASDAQ: IMRN ) is pleased to announce that it has engaged Pullan Consulting to provide business development services to assist in securing a strategic partnership for IMM-529. Pullan Consulting is a highly regarded life sciences advisory firm with a strong track record of executing between f